Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693386 | 0.86 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14GBA1 | |
| SCHEMBL6256081 | 0.82 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14GBA1 | |
| SCHEMBL9219474 | 0.82 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14GBA1 | |
| SCHEMBL23477345 | 0.81 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14GBA1 | |
| SCHEMBL1249634 | 0.81 | EPHX2 (0.43) | HDAC6HDAC1HDAC2CA14 | |
| SCHEMBL2344511 | 0.81 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14GBA1 | |
| SCHEMBL9227134 | 0.81 | HDAC6 (0.46) | HDAC6HDAC1HDAC2CA14GBA1 | |
| SCHEMBL24693051 | 0.80 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA14GBA1 | |
| SCHEMBL8360181 | 0.79 | EPHX2 (0.45) | HDAC6HDAC1HDAC2 | |
| SCHEMBL23113130 | 0.79 | EPHX2 (0.45) | HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-4101855-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-02 | — | — | EP | disclosed |
| WO-2008008442-A1 | PREPARATION AND UTILITY OF HMG-COA REDUCTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007064697-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007062119-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
| WO-2007041630-A1 | DEUTERATED INHIBITORS OF GASTRIC H+, K+-ATPASE WITH ENHANCED THERAPEUTIC PROPERTIES | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
| WO-2006041921-A2 | PREPARATION AND USES OF RHODANINE DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155820-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | HDAC6 1869/4885HDAC1 746/4885HDAC2 1770/4885 |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | ATP4A, ATP6V1G1, ATP6V1E1 | HDAC6 895/4885HDAC1 2041/4885HDAC2 1907/4885 |
| US-20070149622-A1 | Deuterated venlafaxine derivatives formed by decyclization with formic acid; venlafaxine hydrochloride; pharmacokinetics; antiserotonine agents; drug abuse, drug dependence; monoamine neurotransmitters | SLC6A4, HTR4, OPRK1 | HDAC6 811/4885HDAC1 482/4885HDAC2 1604/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | HDAC6 214/4885HDAC1 1513/4885HDAC2 2264/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | HDAC6 327/4885HDAC1 676/4885HDAC2 1881/4885 |
| US-20070112031-A1 | Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties | SLC6A4, HTR4, HTR5A | HDAC6 1825/4885HDAC1 948/4885HDAC2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.